Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
Combining a DNA-damage drug with immunotherapy shows manageable safety in advanced lung and head cancers, opening new combination possibilities.
This phase 1 trial tested ceralasertib, an ATR kinase inhibitor, combined with durvalumab in patients with advanced NSCLC or HNSCC. The study provides first-in-combination safety and efficacy data for this novel DNA damage response-immunotherapy approach.
What the study was
- Study design
- Phase 1 clinical trial
- Population
- Patients with recurrent/metastatic NSCLC or HNSCC
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- British Journal of Cancer
Why it surfaced
First-in-combination data for ATR inhibitor + checkpoint inhibitor in solid tumors. Novel mechanism (DDR + IO). Phase 1 limits design score but high novelty for precision oncology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.